A decade of advances in energy, environmental protection, health sciences and national security for the DOE
Finding new and better ways to detect and treat cancer, Parkinson’s disease and other debilitating diseases; developing new, cleaner and sustainable fuels and technologies to power our vehicles and homes; safeguarding our nuclear weapons; and developing astonishing discoveries that are altering our understanding of the universe – these are just a few examples of research and discoveries performed by the U.S. Department of Energy’s 17 National Laboratories located throughout the country.
As part of an effort to highlight a decade of quality research and innovation at the National Laboratories, the Department today released a commemorative book entitled “A Decade of Discovery.” The National Laboratories throughout this past decade have partnered with industry, business, government agencies, and other researchers in developing discoveries in energy and the environment, national security, and sciences crucial for our communities, the nation, and the world.
“As this book makes clear, collectively the Department’s National Laboratories remain the single greatest scientific enterprise in the world,” said U.S. Energy Secretary Samuel W. Bodman. “As a nation, we will continue to depend on the power and promise of science and engineering to push back the boundaries of what is possible. And therefore we will continue to depend on our National Laboratories and the remarkable men and women who work there.”
Since the founding of the first DOE laboratory more than 60 years ago, the complex has been associated with the recipients of more than 80 Nobel Prizes. “A Decade of Discovery” illuminates the world class advancements in science and technology, energy, and national security at the National Laboratories, a national success story in which all Americans should recognize and take pride.
-
Most popular related searches
Related news
-
Creative Proteomics Cytokine Unveils Disease Cytokine Assays for Disease Diagnosis
Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently announced Disease Cytokine Assays to help researchers obtain higher quality scientific research data. Cytokines, including interleukins, interferons, tumor necrosis factors, and chemokines, can play key pro- and anti-inflammatory...
-
SeqOne Genomics closes €20M series A to accelerate the deployment of its genomic medicine platform
The round, led by Omnes, Merieux Equity Partners, together with the Software Club and existing investors, Elaia and IRDI Capital Investissement, will enable SeqOne Genomics to accelerate its international sales and the development of new collaborative genomic analysis tools to facilitate communications between different disciplines in the medical team, in order to improve patient outcomes in cancer and hereditary disease. The company will intensify investments in the development of its genomic-aware data lake to...
-
Profacgen Helps Accelerate GPCR Study with Various Services
Profacgen, a global provider of drug screening and profiling services that offers a comprehensive panel of services designed to speed and simplify drug discovery research, now offers professional high-throughput GPCR screening services for identification of potential GPCR-targeting drugs. G protein-coupled receptors (GPCRs) are also known as seven-transmembrane domain receptors. They are present only in eukaryotes. Because of their extensive involvement in cellular signal transduction, GPCRs have emerged as...
-
Phase III trial with Nubeqa (darolutamide) in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
ARASENS trial demonstrates an increase in overall survival evaluating darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) compared to docetaxel and ADT, a standard of care in metastatic hormone-sensitive prostate cancer (mHSPC) / Bayer plans to present these pivotal data at a forthcoming scientific congress and to discuss them with health authorities / ARASENS is part of broad development program for darolutamide which includes another ongoing Phase III trial in mHSPC, ARANOTE,...
-
Creative Proteomics Launches Oncology Multi-omics Platform to Promote Basic Oncology Research
Using its mature multi-omics technology platform, Creative Proteomics has been devoted to providing high-quality, personalized oncology multi-omics services and reliable data support to worldwide clients for years. With the continuous aging of human society, the improvement of industrialization, and the deterioration of the quality of living environment, the incidence of cancer is getting higher and higher. Elucidating the mechanisms of tumorigenesis is utterly dire and a crucial research topic. The use of...
Customer comments
No comments were found for A decade of advances in energy, environmental protection, health sciences and national security for the DOE. Be the first to comment!